Clinerion and Datametrix announced a new partnership in which the organizations will generate real-world evidence (RWE) insights using real-world data (RWD) from Clinerion’s hospital network.
According to a press release, the joint effort will support “pharmaceutical companies with optimization of clinical study design to meet strategic development needs.”
“We believe that data collected in an organized and simple manner, then analyzed using the right analytical tools will empower pharmaceutical and biotechnology companies to bring better drugs to market faster,” Datametrix CEO Ahmed Rhali said in a statement. “Together, Datametrix and Clinerion can power Real World Evidence research and bring insights in the realities of clinical practice, which is acutely relevant for [the] pharmaceutical industry, field-leading clinicians, hospital management, healthcare policy makers and, of course, patients.”
To read the full press release, click here.
